A new study shows that the number of bariatric surgeries are decreasing as more patients treating obesity seek out ...
The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...
With the rising demand for weight-loss medications, compounding pharmacies have been making headlines lately. On October 30, ...
Newer medications to treat diabetes and obesity are saving lives, but those who need the injectable drugs the most, were the ...
The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, ...
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...
Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial in patients with a type of fatty ...
People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...
Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.
Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial by showing improvement in liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback